about
Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesisSeroprevalence of HTLV-1 and HTLV-2 amongst mothers and children in Malawi within the context of a systematic review and meta-analysis of HTLV seroprevalence in AfricaOptimizing Management of Patients with Adult T Cell Leukemia-LymphomaOrigin and prevalence of human T-lymphotropic virus type 1 (HTLV-1) and type 2 (HTLV-2) among indigenous populations in the AmericasAutoimmunity and infection in Sjögren's syndromeHuman T-lymphotropic virus type 1 in coastal natives of British Columbia: phylogenetic affinities and possible originsA source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.Identification of a domain within the human T-cell leukemia virus type 2 envelope required for syncytium induction and replicationDiscrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease.Detection of human T-lymphotropic virus (HTLV) tax sequences in New York City blood donors seronegative for HTLV types 1 and 2Immunogenetics and the Pathological Mechanisms of Human T-Cell Leukemia VirusType 1- (HTLV-1-)Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I.HTLV-1 infectionsOcular manifestations and pathology of adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus type 1.Expansion in CD39⁺ CD4⁺ immunoregulatory t cells and rarity of Th17 cells in HTLV-1 infected patients is associated with neurological complications.Control of the inflammatory response mechanisms mediated by natural and induced regulatory T-cells in HCV-, HTLV-1-, and EBV-associated cancers.In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome.Detrusor Arreflexia as an End Stage of Neurogenic Bladder in HAM/TSP?Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trialIsokinetic trunk and knee muscle strengths and gait performance in walking patients with T-cell lymphotropic virus type 1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP).Is Sjögren's syndrome a retroviral disease?Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.Hospital admissions for human T-cell lymphotropic virus type-1 (HTLV-1) associated diseases in Dominica.Human T-cell Lymphotropic Virus types I and II (HTLV-I/II) in French Guiana: clinical and molecular epidemiology.Functional impairment of Tax-specific but not cytomegalovirus-specific CD8+ T lymphocytes in a minor population of asymptomatic human T-cell leukemia virus type 1-carriersCharacterization of an infectious molecular clone of human T-cell leukemia virus type I.Genes in the pX region of human T cell leukemia virus I influence Vav phosphorylation in T cells.Tumor necrosis factor alpha inhibitors have no effect on a human T-lymphotropic virus type-I (HTLV-I)-infected cell line from patients with HTLV-I-associated myelopathy.Cytokine profile and proviral load among Japanese immigrants and non-Japanese infected with HTLV-1 in a non-endemic area of BrazilIncreased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T Cells detected by peptide-specific, major histocompatibility complex-restricted antibodies iEpidemiological Aspects and World Distribution of HTLV-1 Infection.The Prevalence of Human T-Cell lymphotropic Virus Type 1 in Pregnant Women and Their NewbornsImmunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectivesUpdate on the therapy of highly aggressive non-Hodgkin's lymphoma.Human endogenous retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods.HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) AND HUMAN T-LYMPHOTROPIC VIRUS 2 (HTLV-2): GEOGRAPHICAL RESEARCH TRENDS AND COLLABORATION NETWORKS (1989-2012)Animals Models of Human T Cell Leukemia Virus Type I Leukemogenesis.Distinct Morphology of Human T-Cell Leukemia Virus Type 1-Like Particles.Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP.Human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis: viral load and muscle tone are correlated.
P2860
Q21131133-35A36ABA-0917-4920-9DB3-6B463396883CQ26772130-7DEC3224-20A7-4F0E-936F-BD8A74D059D0Q26776521-DF4AC31E-9BF2-4BB7-B4C5-7CC48DD0660CQ26996748-E7C17F98-599C-4ECD-88AE-494CC7251373Q27026174-59D22F42-6DDC-4E0D-8D25-C6055B76338BQ28775727-DF398A9F-01FF-4418-BDE5-98D9471D6125Q30425683-ED31EC85-28EF-49CF-BF80-C4FA94E4BF21Q30453537-DAB81425-EADC-4B65-8994-F9759C824253Q31172613-9E3B72EF-BA7A-4062-A1CC-4985FC3F2F5DQ33187703-F6E8F5C4-17F8-4134-99A6-BC81857473E5Q33651831-C81AB442-4846-4D0A-888C-98025A5251A2Q33655605-5D475A7B-E19E-47B5-8768-6C1764E48549Q34043666-BD6445D7-D82B-442C-B823-CA92F05BEA0CQ34483312-4AB1356E-49D7-45BC-899F-A79DBA5D3AE1Q34587031-A59F920C-35F3-46A1-BEE3-54E40F699E7CQ34708248-41BCD19A-DC0D-41DE-9985-DE0B2A25640DQ34764429-5ECC8FE7-3853-4C9B-B07C-4A305EC711FAQ34897044-E7EE0E67-DAAB-439A-8E7D-34AF81D184AFQ34941384-FAC551CD-3B14-4757-A115-F7A8C14814C8Q35047215-0D8F7695-ABE3-4950-BF62-AC028AF95D3DQ35092867-EA6EB424-ED35-4A0D-9ECF-66C58A9D3596Q35261563-F93E2040-CCBD-4F6D-AFA1-3C3051C9CDF3Q35516989-5FFC07C4-0661-4650-B267-0C202C1A2B19Q35604280-1B7D7785-A0E5-4A7F-9F84-D456D0F0C2AAQ35682461-56422B0F-92A6-47DC-B9B7-A608DE69EFA2Q35837041-A1082DD8-BCE7-454B-AC20-2EE4E5FEE6C3Q35890828-DE63AA91-C37F-4495-B681-C58209FCA770Q36270244-6D00C250-813A-4C55-B032-48192DEA8A63Q36334037-86C90B8A-AFB6-4690-8B38-BF257C909987Q36399192-949D5D58-3596-4494-8E9C-A18026281DE0Q36400825-7CBC3773-E0B3-42CD-BC95-A93AF92BCBD2Q36421218-C75AC8EA-8457-4755-A397-6EAC59B18793Q36422111-565525BC-450E-4AD0-BB72-92939AA84A5FQ36521840-FF304E97-FCA6-4CEE-9F39-856808AC7670Q36575342-EC90FBA5-427A-4DE1-8A95-8FE9D3007B0CQ36692320-BBDD9B6E-2DC7-4871-9A1D-E530C2CDCFBAQ36751592-E3EC2302-A9EF-4105-A575-3AA119A57581Q36947017-01E8CAC2-9973-4338-9518-379A471B49A0Q36995018-BFD08750-B565-4B36-B115-DD76164621A0Q37226460-A84DAA6F-57CE-4B91-BA06-E2DC2C0825BA
P2860
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
An HTLV-I vaccine: why, how, for whom?
@en
type
label
An HTLV-I vaccine: why, how, for whom?
@en
prefLabel
An HTLV-I vaccine: why, how, for whom?
@en
P356
P1476
An HTLV-I vaccine: why, how, for whom?
@en
P2093
P304
P356
10.1089/AID.1993.9.381
P577
1993-05-01T00:00:00Z